RecruitingNCT07492927
Plasma exoRNA-Based Liquid Biopsy to Diagnose Clinically Significant Prostate Cancer
Sponsor
Xijing Hospital
Enrollment
1,700 participants
Start Date
Mar 12, 2021
Study Type
OBSERVATIONAL
Conditions
Summary
The aim of the present study is to investigate a plasma exosome RNA signature to diagnose clinically significant prostate cancer.
Eligibility
Sex: MALEMin Age: 18 Years
Inclusion Criteria3
- Blood prostate-specific antigen PSA>4ng/dl;
- Patients suspected of having prostate cancer through clinical symptoms, digital rectal examination, ultrasound examination, magnetic resonance imaging.
- The patient is willing to undergo prostate biopsy.
Exclusion Criteria3
- Previous diagnosis of prostate cancer through prostate biopsy;
- History of other malignant tumors in the past two years;
- According to the research physician''s judgment, serious complications may occur and affect the normal conduct of the experiment
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(10)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07492927